Wyndham Worldwide Corp (WYN) Falls 3.61% for February 02

Equities Staff |

One of the S&P 500’s big losers for Tuesday February 02 was Wyndham Worldwide Corp (WYN). The company’s stock fell 3.61% to $62.70 on volume of 973,702 shares.

The stock opened the day at 64.05 and traded between a low of $62.42 and a high of $64.63. The stock finished the day down $2.35 per share. Wyndham Worldwide Corp has an average daily volume of 1.27 million and a total float of 116.11 million shares. The 50-day SMA for Wyndham Worldwide Corp is $71.42 and its 200-day SMA is $78.31. The high for the stock over the last 52 weeks is $94.35 and the low is $61.72.

Wyndham Worldwide Corp is a hospitality company, offering individual consumers and business customers a suite of hospitality products and services. It operates three segments including, lodging, vacation exchange and rentals and vacation ownership.

Wyndham Worldwide Corp is centered in Parsippany, NJ, and has 34,400 employees. Today’s trading day leaves the company with a market cap of $7.28 billion. The company has a P/S ratio of n/a, P/B ratio of 7.17, and a 18.5.

For a complete fundamental analysis analysis of Wyndham Worldwide Corp, check out Equities.com’s Stock Valuation Analysis report for WYN. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…


Autonomous security robots providing advanced detection capabilities at $7 per hour - aiming to define the future of security. Help #StopTheViolence.